Q: Why is Prothena partnering with Walgreens?
A: Our collaboration with Walgreens should accelerate patient identification and increase access and recruitment for Prothena’s ongoing ASCENT-2 multiple ascending dose clinical trial, which is evaluating the safety and tolerability of PRX012. PRX012 is a potential best-in-class anti-Aβ antibody under development for the treatment of Alzheimer’s disease that has been granted Fast Track designation by the U.S. Food and Drug Administration.
For more information about the ASCENT clinical trial, visit ASCENT-AD.com.
Q: What makes Walgreens the right partner for Prothena?
A: There are a few qualities that make Walgreens a great partner for us, but the clearest is their commitment to patients, which is a value that we also hold deeply at Prothena. Keeping this value at the forefront of our partnership has made it an enjoyable collaboration.
Additionally, Walgreens has an incredible U.S. footprint, which allows us to reach large numbers of patients across the US. Coupling this with the trusted relationship between patients and their community pharmacist, we believe that we can reach a broad and diverse patient population, who may otherwise never know about – or consider participating in – a clinical trial.
Q: How does Prothena’s recent partnership with Walgreens help reach a more diverse community for recruiting for the ASCENT-2 clinical trial?
A: Typically, clinical trial sites enroll study participants who are already known to them, are referred by community physicians, or who respond to various forms of outreach like advertising or social media. The Walgreens collaboration allows us to supplement these traditional efforts and reach a much broader group of patients through Walgreens national portfolio; these are people who otherwise may not learn about the trial opportunity through traditional means.
Q: Tell us more about why partnerships like this one are important to the industry.
A: To reach a diverse population of patients affected by disease, we need to be expansive in our approach to identifying them. Doing so means collaborating with partners who are courageous, innovative, and committed. We know we can accomplish a lot on our own, but we can achieve so much more working with trusted partners.
Q: Why is accelerating enrollment in the ASCENT-2 trial so important?
A: In short, it’s because every day counts. It’s estimated that nearly 50 million people globally are living with Alzheimer’s disease, and that number is expected to increase rapidly with our aging population. Currently, Alzheimer’s disease is the 7th leading cause of death in the US with a projected economic burden on the US healthcare system of $1 trillion annually by 2050. It’s a dreadful disease that impacts not only patients, but their family members, caregivers, and loved ones.
This is why we’re advancing one of the most robust Alzheimer’s disease portfolios in the industry, guided by our comprehensive therapeutic strategy, and supported by a team of caring and committed individuals – both at Prothena and Walgreens.
Learn more about Prothena’s partnership with Walgreens here.